Evidence map›Paper›PMID 36188659›Full record

ArticleJournal of medicine and life2022

GIST: Correlation of risk classifications and outcome.

Sabine Kersting, Monika Silvia Janot-Matuschek, Carina Schnitzler, Daniel Enrique Chourio Barboza, Waldemar Uhl, Ulrich Mittelkötter

Abstract read
In one paragraph

Article in Journal of medicine and life, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sabine KerstingDepartment of General Surgery, Christliches Klinikum Unna Mitte, Unna, Germany.
Monika Silvia Janot-MatuschekDepartment of General Surgery, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Carina SchnitzlerDepartment of General Surgery, Christliches Klinikum Unna Mitte, Unna, Germany.
Daniel Enrique Chourio BarbozaDepartment of General Surgery, Christliches Klinikum Unna Mitte, Unna, Germany.
Waldemar UhlDepartment of General Surgery, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Ulrich MittelkötterDepartment of General Surgery, Christliches Klinikum Unna Mitte, Unna, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In clinical practice, there are often discrepancies between the oncological prognosis of gastrointestinal stromal tumors (GIST) and the actual clinical course. This study aimed to check with our collective how reliably the current classifications (Miettinen, Fletcher) predict the prognosis of GIST and to evaluate whether an extension of the classifications by the parameter proliferation activity could make sense. This prospective study enrolled 58 patients who underwent surgery on GIST from 01/2006 to 12/2016. The postoperative course (curation, recurrence, progress) was correlated with the identified risk classification and the proliferative activity. Coincidences with other tumors were strikingly common in patients with GIST (43%). Based on the risk group assignment of GIST, no assessment of the probability of the occurrence of second neoplasia could be derived. Individual patients were under- or over-graduated concerning the assessment of biological behavior based on the standard risk classifications. The inclusion of proliferative activity did not allow for a more precise predictive power - neither to the risk of recurrence and metastasis nor to the development of a second neoplasia. The study showed that there is currently no parameter or logarithm that reliably predicts the biological behavior of GIST. Due to the frequency of coincidence of second neoplasia and (rare) distant metastases, for everyday clinical practice, appropriate staging diagnostic and regular follow-up care should also be used for benign GIST.

Indexed as

Gastrointestinal Stromal TumorsHumansMutationPrognosisProspective StudiesProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaRetrospective StudiesProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaCD – cluster of differentiationDOG – discovered on gastrointestinal stromal tumors proteinGastrointestinal stromal tumor (GIST)GIST – gastrointestinal stromal tumorHPF – high-power fieldIPMN – intraductal papillary mucinous neoplasmKIT – stem cell factor receptor, tyrosine kinasemetastasis riskMIB – made in borstelNIH – National Institutes of HealthPDGFRA – platelet-derived growth factorproliferation raterecurrence risksecondary neoplasiaTNM – tumor nodes metastasesUICC – Union Internationale Contre le Cancer

Identifiers

PMID36188659
PMCPMC9514809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.